ArticleClinical immunology (Orlando, Fla.)2015
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
Article in Clinical immunology (Orlando, Fla.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- European S2k Guideline on Chronic PruritusActa dermato-venereologica · 2025Guideline
- IL-31: State of the Art for an Inflammation-Oriented Interleukin.International journal of molecular sciences · 2022Pooled it
- IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.Drugs · 2021Pooled it
- Successful use of nemolizumab for refractory pruritus in cutaneous T-cell lymphoma.JAAD case reports · 2026Article
- Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026Review
- From neuroimmune circuits to targeted therapy of chronic pruritus.Pharmacological reviews · 2026Review
- Atopic Dermatitis beyond Eczema: A Review on its Systemic Impact through Pruritus and Associated Comorbidities.Clinical reviews in allergy & immunology · 2025Review
- Editorial: Cytokines and chemokines in lymphoma.Frontiers in immunology · 2025Article
- Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.Clinical and experimental medicine · 2024Article
- Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma.Life (Basel, Switzerland) · 2024Review
- What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus.American journal of clinical dermatology · 2024Review
- Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations.Blood advances · 2023Article
- Clinical implications of interleukins-31, 32, and 33 in gastric cancer.World journal of gastrointestinal oncology · 2022Article
- Post-Translational Modifications in Atopic Dermatitis: Current Research and Clinical Relevance.Frontiers in cell and developmental biology · 2022Review
- Peripheral Mechanisms of Itch.The Journal of investigative dermatology · 2022Review
- Pruritus in Keloid Scars: Mechanisms and Treatments.Acta dermato-venereologica · 2021Review
- IL-31, itch and hematological malignancies.Clinical and molecular allergy : CMA · 2021Review
- Interleukin-31 and Pruritic Skin.Journal of clinical medicine · 2021Review
- Pruritus as a Distinctive Feature of Type 2 Inflammation.Vaccines · 2021Review
- The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.Journal of the American Academy of Dermatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.